|
To continue, please scroll down to the bottom of the page to confirm you have read
the CME Accreditation information.
|
HARDWARE AND SOFTWARE SPECIFICATIONS NEEDED TO VIEW SITE
|
Printer-friendly version |
|
This course requires Windows Operating Systems (95/98, NT, 2000, ME, XP), version 5.5 browsers or higher from Microsoft or Netscape.
Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be: Macromedia Flash, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.
|
Back to top  |
| |
|
ACCREDITATION STATEMENT
|
|
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Elsevier Office of Continuing Medical Education (EOCME) and Excerpta Medica, Inc. The EOCME is accredited by the ACCME to provide continuing medical education (CME) for physicians.
|
|
Back to top |
| |
|
CREDIT DESIGNATION STATEMENT
|
|
The EOCME designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
|
|
Back to top |
| |
|
DISCLOSURES
|
|
As a sponsor accredited by the ACCME, it is the policy of the EOCME to require the disclosure of anyone who is in a position to control the content of an educational activity. All relevant financial relationships with any commercial interests and/or manufacturers must be disclosed to participants at the beginning of each activity. The faculty of this CME activity disclose the following:
|
Faculty Member
|
|
Manufacturer
|
|
Relationship
|
| Marc Cohen, MD |
|
sanofi-aventis U.S. |
|
Grants/Research Support, Speaker’s Bureau |
| |
|
Bristol-Myers Squibb, Schering-Plough |
|
Speaker’s Bureau |
| Deepak L. Bhatt, MD |
|
Bristol-Myers Squibb, sanofi-aventis U.S., The Medicines Company |
|
Speaker’s Bureau |
| |
|
AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Eisai, GlaxoSmithKline, Millennium, ParinGenix, Protein Design Labs, sanofi-aventis U.S., Schering-Plough, The Medicines Company |
|
Consultant/Advisory Board |
| Geno J. Merli, MD |
|
sanofi-aventis U.S., AstraZeneca |
|
Grants/Research Support, Consultant, Speaker’s Bureau |
| |
|
Bacchus Vascular, Inc. |
|
Consultant |
| |
|
Bayer Pharmaceuticals Corporation |
|
Grants/Research Support |
| Activity Director |
|
|
|
|
| Paul Ruest, PhD |
|
Excerpta Medica |
|
Nothing to Disclose |
| Jennifer DiBenedetto |
|
EOCME |
|
Nothing to Disclose |
|
|
Back to top |
| |
|
RESOLUTION OF CONFLICT OF INTEREST
|
|
The EOCME has implemented a process to resolve conflicts of interest for each CME activity. In order to help ensure content objectivity, independence, fair balance, and that the content is aligned with the interest of the public, the EOCME has resolved the conflict by by external content review.
|
|
Back to top |
| |
|
UNAPPROVED/OFF-LABEL USE DISCLOSURE
|
|
The EOCME requires CME faculty to disclose to the participants:
1. When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and
2. Any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.
Faculty may discuss information about pharmaceutical agents that is outside of FDA-approved labeling. This information is intended solely for CME and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
|
|
Back to top |
| |
|
INTENDED AUDIENCE
|
|
This activity is being developed for cardiologists, interventional cardiologists, cardiac surgeons, and emergency department (ED) physicians.
|
|
Back to top |
| |
|
PROGRAM GOAL
|
|
The goal of this activity is to introduce and provide data on the importance of reducing door-to-treatment times.
|
|
Back to top |
| |
|
EDUCATIONAL OBJECTIVES
|
|
After completing this educational activity and the post-test, participants should be able to:
- Discuss the importance of reducing door-to-treatment times
- Name 6 techniques that can be applied in the hospital that have been demonstrated to reduce door-to-treatment times
- Understand how to apply techniques in their own institutions in order to decrease door-to-treatment times
- Identify barriers commonly encountered in the ED that must be overcome in order to reduce door-to-treatment times
- Describe changes in ED staff behavior that are necessary in order to reduce door-to-treatment times
- Describe the findings of research on the current strategies that are employed and understand the flaws that may be associated with ineffective communication between clinical departments
- Explain the overall importance of this clinical initiative
Release Date of Activity: 6/27/2007
Expiration Date of Activity for AMA PRA Credit: 7/31/2009
Estimated Time to Complete This Activity: 1
|
|
Back to top |
| |
|
FINANCIAL SUPPORT
|
|
This CME activity is supported by an educational grant from sanofi-aventis U.S.
|
|
Back to top |
| |
|
CME PLANNING COMMITTEE
|
|
Marc Cohen, MD
Deepak L. Bhatt, MD
Geno J. Merli, MD
Paul Ruest, PhD
Jennifer DiBenedetto
|
|
Back to top |
| |
|
SPECIAL NEEDS
|
|
We encourage participation by all individuals. If you have any special needs, please contact Sharon Liuzza at (908) 547-2178, or s.liuzza@elsevier.com for assistance.
|
|
Back to top |
| |
|